Regulated Shedding of Syndecan-1 and -4 Ectodomains by Thrombin and Growth Factor Receptor Activation*
Abstract
The syndecan family of transmembrane heparan sulfate proteoglycans is abundant on the surface of all adherent mammalian cells. Syndecans bind and modify the action of various growth factors/cytokines, proteases/antiproteases, cell adhesion molecules, and extracellular matrix components. Syndecan expression is highly regulated during wound repair, a process orchestrated by many of these effectors. Each syndecan ectodomain is shed constitutively by cultured cells, but the mechanism and significance of this shedding are not understood. Therefore, we examined (i) whether physiological agents active during wound repair influence syndecan shedding, and (ii) whether wound fluids contain shed syndecan ectodomains.
Using SVEC4–10 endothelial cells we find that certain proteases and growth factors accelerate shedding of the syndecan-1 and -4 ectodomains. Protease-accelerated shedding is completely inhibited by serum-containing media. Thrombin activity is duplicated by the 14-amino acid thrombin receptor agonist peptide that directly activates the thrombin receptor and is not inhibited by serum. Epidermal growth factor family members accelerate shedding but FGF-2, platelet-derived growth factor-AB, transforming growth factor-β, tumor necrosis factor-α, and vascular endothelial cell growth factor 165 do not. Shed ectodomains are soluble, stable in the conditioned medium, have the same size core proteins regardless whether shed at a basal rate, or accelerated by thrombin or epidermal growth factor-family members and are found in acute human dermal wound fluids. Thus, shedding is accelerated by activation of at least two distinct receptor classes, G protein-coupled (thrombin) and protein tyrosine kinase (epidermal growth factor). Proteases and growth factors active during wound repair can accelerate syndecan shedding from cell surfaces. Regulated shedding of syndecans suggests physiological roles for the soluble proteoglycan ectodomains.
Footnotes
-
↵* This work was supported by National Institutes of Health predoctoral training Grant 5T32NS07264–13 (to M. F.), National Institutes of Health training Grant HD07466 (to S. S.), and National Institutes of Health Grants CA28735, HD06763, and HL46491 (to M. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵‡ Contributed equally to the results in this report.
-
↵§ To whom correspondence should be addressed: Joint Program in Neonatology, Harvard Medical School, 300 Longwood Ave., Boston, MA 02115. Tel.: 617-355-6366; Fax: 617-355-7677; E-mail:bernfield{at}a1.tch.harvard.edu.
-
↵1 The abbreviations used are: HB-EGF, heparin-binding epidermal growth factor-like growth factor; EGF, epidermal growth factor; FGF-2, fibroblast growth factor-2; TGF-α, transforming growth factor-α; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; FCS, fetal calf serum; GAG, glycosaminoglycan; PMA, phorbol 12-myristate 13-acetate; TRAP, thrombin receptor agonist peptide; TPCK,l-1-tosylamido-2-phenylethyl chloromethyl ketone; CM, conditioned medium; HSE-1, serum antibody against human syndecan-1 ectodomain; AU, absorbance unit(s); PAGE, polyacrylamide gel electrophoresis; mAbs, monoclonal antibody.
-
- Received September 27, 1996.
- Revision received March 26, 1997.











